Tectonic Therapeutic (TECX) EBIAT (2017 - 2026)
Tectonic Therapeutic (TECX) has 10 years of EBIAT data on record, last reported at -$25.2 million in Q1 2026.
- On a quarterly basis, EBIAT fell 58.75% to -$25.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$83.5 million, a 42.32% decrease, with the full-year FY2025 number at -$74.2 million, down 27.85% from a year prior.
- EBIAT reached -$25.2 million in Q1 2026 per TECX's latest filing, down from -$19.3 million in the prior quarter.
- Over the last five years, EBIAT for TECX hit a ceiling of -$7.8 million in Q4 2023 and a floor of -$29.8 million in Q1 2022.
- A 5-year average of -$18.0 million and a median of -$17.7 million in 2024 define the central range for EBIAT.
- Peak YoY movement for EBIAT: skyrocketed 68.66% in 2023, then crashed 76.22% in 2024.
- Tracing TECX's EBIAT over 5 years: stood at -$25.0 million in 2022, then surged by 68.66% to -$7.8 million in 2023, then crashed by 57.93% to -$12.4 million in 2024, then crashed by 55.36% to -$19.3 million in 2025, then tumbled by 31.12% to -$25.2 million in 2026.
- Business Quant data shows EBIAT for TECX at -$25.2 million in Q1 2026, -$19.3 million in Q4 2025, and -$19.0 million in Q3 2025.